The IPLD-treated mice had as high as 53.6% CD80+CD86+ mDCs in TDLNs compared with 24.6% in the PLD-treated mice and 11.0% in the PBS group (Fig. 6d,e), promoting the recruitment of T cells into the tumours (Supplementary Fig. 69). The gene discussed is CD86; the disease is neoplasm.